

■ Biocon Q2 Consolidated Net Profit Jumps to ₹306 crore



NEW DELHI: Biotechnology major Biocon reported a jump in its consolidated net profit to ₹306 crore for the second quarter ended September 30, 2015. The company had posted a net profit of ₹102 crore in the same period a year ago, Biocon said in filing to the BSE. "It has been a landmark quarter for Biocon with the hugely-successful listing of Syngene. We are extremely proud and excited to take Syngene to its next phase of growth. For second quarter of FY16, Syngene reported a revenue growth of 30%," Biocon chairperson and MD Kiran Mazumdar-Shaw said. The consolidated revenue of Biocon was up by 11.38% at ₹861 crore during the quarter compared to ₹773 crore in the year-ago period. "It has been a stable performance for Biocon this quarter with several growth triggers on the horizon focusing on Biosimilars in emerging markets," she said. Shaw said the clinical advancement of five of Biocon's Biosimilars programmes has put the company on track for regulatory filings for some of these in the US & Europe in FY17. – PTI